Research progress of transcranial ultrasound in the clinical diagnosis of Parkinson′s disease
CAO Shuangshuang1 WANG Jianwei1 WANG Zhan2,3 MA Huizi2,3 FENG Tao2,3,4
1.Department of Neurology, Yidu Central Hospital of Weifang, Shandong Province, Qingzhou 262500, China;
2.Department of Motion Disorders, Center for Neurodegenerative Disease, Beijing Tiantan Hospital, Capital Medical University，Beijing 100070，China;
3.China National Clinical Research Center for Neurological Disease, Beijing 100050, China; 4.Parkinson′s Disease Center, Beijing Institute for Brain Disorder, Capital Medical University, Beijing 100050, China
Abstract：In the past two decades, transcranial ultrasound (TCS) examination has been used more and more in the diagnosis and differential diagnosis of movement disorders. Compared with other imaging inspection methods, such as computed tomography, as well as magnetic resonance imaging and positron emission tomography, TCS is worthy of promotion with the advantages of lower cost, more convenient and non-invasive operation. However, the results of TCS examination are affected by many factors, such as the patient′s temporal window display, the difference in the performance of the substantia nigra, the examiner′s experience and other factors, so the validity of the examination results is controversial. Due to the great clinical heterogeneity of Parkinson′s disease, the diagnosis of Parkinson′s disease requires a combination of clinical manifestations and multiple auxiliary examinations. Transcranial ultrasound can be used as an imaging marker to provide supporting evidence for the diagnosis of Parkinson′s disease. This paper describes the examination methods, determination criteria and possible mechanisms of transcranial substantia nigra in details. Furthermore, we have summarized and analyzed the value of TCS in the diagnosis, differential diagnosis and monitoring of high-risk populations in Parkinson′s disease, and pointed out its limitations with improving direction to help the better application in the further.
曹双双1 王建伟1 王展2,3 马惠姿2,3 冯涛2,3,4. 经颅超声在帕金森病临床诊断中的研究进展[J]. 中国医药导报, 2020, 17(18): 53-56.
CAO Shuangshuang1 WANG Jianwei1 WANG Zhan2,3 MA Huizi2,3 FENG Tao2,3,4. Research progress of transcranial ultrasound in the clinical diagnosis of Parkinson′s disease. 中国医药导报, 2020, 17(18): 53-56.
[1] Poewe W. Smelling Parkinson′s Disease：New Metabolomic Biomarker for PD [J]. ACS Cent Sci，2019，5（4）：575-576.
[2] Lotankar S，Prabhavalkar KS，Bhatt LK. Biomarkers for Parkinson′s Disease：Recent Advancement [J]. Neurosci Bull，2017，33（5）：585-597.
[3] Yilmaz R，Berg D. Transcranial B-Mode Sonography in Movement Disorders [J]. Int Rev Neurobiol，2018，143：179-212.
[4] Walter U. How to measure substantia nigra hyperechogenicity in Parkinson disease：detailed guide with video [J]. J Ultrasound Med，2013，32（10）：1837-1843.
[5] Huang YW，Jeng JS，Tsai CF，et al. Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson′s disease [J]. Mov Disord，2007，22（4）：550-555.
[6] Jiang H，Wang J，Rogers J，et al. Brain Iron Metabolism Dysfunction in Parkinson′s Disease [J]. Mol Neurobiol，2017，54（4）：3078-3101.
[7] Zhu Y，Wang B，Tao K，et al. Iron accumulation and microglia activation contribute to substantia nigra hyperechogenicity in the 6-OHDA-induced rat model of Parkinson′s disease [J]. Parkinsonism Relat Disord，2017，36：76-82.
[8] Yu SY，Cao CJ，Zuo LJ，et al. Clinical features and dysfunctions of iron metabolism in Parkinson disease patients with hyper echogenicity in substantia nigra：a cross-sectional study [J]. BMC Neurol，2018，18（1）：9.
[9] Shafieesabet A，Fereshtehnejad SM，Shafieesabet A，et al. Hyperechogenicity of substantia nigra for differential diagnosis of Parkinson's disease：A meta-analysis [J]. Parkinsonism Relat Disord，2017，42：1-11.
[10] Bor-Seng-Shu E，Paschoal FM，Almeida KJ，et al. Transcranial brain sonography for Parkinsonian syndromes [J]. J Neurosurg Sci，2019，63（4）：441-449.
[11] Berardelli A，Wenning GK，Antonini A，et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson′s disease [J]. Eur J Neurol，2013，20（1）：16-34.
[12] Walter U，?譒koloudík D. Transcranial sonography （TCS） of brain parenchyma in movement disorders：quality standards，diagnostic applications and novel technologies [J]. Ultraschall Med，2014，35（4）：322-331.
[13] Bouwmans AE，Vlaar AM，Srulijes K，et al. Transcranial sonography for the discrimination of idiopathic Parkinson′s disease from the atypical parkinsonian syndromes [J]. Int Rev Neurobiol，2010，90：121-146.
[14] Richter D，Katsanos AH，Schroeder C，et al. Lentiform Nucleus Hyperechogenicity in Parkinsonian Syndromes：A Systematic Review and Meta-Analysis with Consideration of Molecular Pathology [J]. Cells，2019，9（1）：1-9.
[15] Alonso-Canovas A，Tembl Ferrairó JI，Martínez-Torres I，et al. Transcranial sonography in atypical parkinsonism：How reliable is it in real clinical practice? A multicentre comprehensive study [J]. Parkinsonism Relat Disord，2019，68：40-45.
[16] Jesus-Ribeiro J，Freire A，Sargento-Freitas J，et al. Transcranial Sonography and DaTSCAN in Early Stage Parkinson′s Disease and Essential Tremor [J]. Eur Neurol，2016，76（5/6）：252-255.
[17] Cardaioli G，Ripandelli F，Paolini Paoletti F，et al. Substantia nigra hyperechogenicity in essential tremor and Parkinson′s disease：a longitudinal study [J]. Eur J Neurol，2019，26（11）：1370-1376.
[18] Walter U，Skoloudík D，Berg D. Transcranial sonography findings related to non-motor features of Parkinson′s disease [J]. J Neurol Sci，2010，289（1/2）：123-127.
[19] Liu XJ，Zhang L，Zhang YF，et al. Echogenic alteration in the raphe nuclei measured by transcranial sonography in patients with Parkinson disease and depression [J]. Medicine （Baltimore），2018，97（50）：e13524.
[20] Iranzo A，Stockner H，Serradell M，et al. Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder [J]. Mov Disord，2014，29（14）：1774-1780.
[21] Toomsoo T，Liepelt-Scarfone I，Kerner R，et al. Substantia Nigra Hyperechogenicity：Validation of Transcranial Sonography for Parkinson Disease Diagnosis in a Large Estonian Cohort [J]. J Ultrasound Med，2016，35（1）：17-23.
[22] Zhou HY，Huang P，Sun Q，et al. The role of substantia nigra sonography in the differentiation of Parkinson's disease and multiple system atrophy [J]. Transl Neurodegener，2018，7：15-22.
[23] Liu P，Li X，Li FF，et al. The predictive value of transcranial sonography in clinically diagnosed patients with early stage Parkinson′s disease：comparison with DAT PET scans [J]. Neurosci Lett，2014，582：99-103.
[24] Li DH，Zhang LY，Hu YY，et al. Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson′s disease [J]. Parkinsonism Relat Disord，2015，21（8）：923-928.
[25] Alonso-Canovas A，Lopez-Sendon Moreno JL，Buisan J，et al. Does normal substantia nigra echogenicity make a difference in Parkinson′s disease diagnosis? A real clinical practice follow-up study [J]. J Neurol，2018，265（10）：2363-2369.
[26] Zhou HY，Sun Q，Tan YY，et al. Substantia nigra echogenicity correlated with clinical features of Parkinson′s disease [J]. Parkinsonism Relat Disord，2016，24：28-33.
[27] Skoloudik D，Jelinkova M，Blahuta J，et al. Transcranial sonography of the substantia Nigra：Digital image analysis [J]. AJNR Am J Neuroradiol，2014，35（12）：2273-2278.
[28] Fei XY，Dong Y，An HD，et al. Impact of region of interest size on transcranial sonography based computer-aided diagnosis for Parkinson′s disease [J]. Math Biosci Eng，2019，16（5）：5640-5651.
[29] Plate A，Ahmadi SA，Pauly O，et al. Three-dimensional sonographic examination of the midbrain for computer-aided diagnosis of movement disorders [J]. Ultrasound Med Biol，2012，38（12）：2041-2050.
[30] Plate A，Maiostre J，Levin J，et al. A baseline study for detection of Parkinson′s disease with 3D-transcranial sonography and uni-lateral reconstruction [J]. J Neurol Sci，2019，397：16-21.
[31] Shi J，Yan M，Dong Y，et al. Multiple Kernel Learning Based Classification of Parkinson′s Disease With Multi-Modal Transcranial Sonography [C]. Conf Proc IEEE Eng Med Biol Soc，2018：61-64.
2020, Vol. 17 
京公网安备 11010502046598号